Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pola Olczak"'
Autor:
Hsin-Fang Tu, Margaret Wong, Ssu-Hsueh Tseng, Nattha Ingavat, Pola Olczak, Kin Israel Notarte, Chien-fu Hung, Richard B.S. Roden
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-15 (2024)
Abstract Background MUC16 is a heavily glycosylated cell surface mucin cleaved in the tumor microenvironment to shed CA125. CA125 is a serum biomarker expressed by > 95% of non-mucinous advanced stage epithelial ovarian cancers. MUC16/CA125 contribut
Externí odkaz:
https://doaj.org/article/ad877e31f2644c21920641ea86e35a8b
Autor:
Pola Olczak, Richard B.S. Roden
Publikováno v:
Vaccines, Vol 8, Iss 4, p 568 (2020)
The human papillomaviruses (HPVs) are a family of small DNA tumor viruses including over 200 genotypes classified by phylogeny into several genera. Different genera of HPVs cause ano-genital and oropharyngeal cancers, skin cancers, as well as benign
Externí odkaz:
https://doaj.org/article/47939688f9724d5da4dbe488a7242b94
Autor:
Pola Olczak, Margaret Wong, Hua-Ling Tsai, Hao Wang, Reinhard Kirnbauer, Andrew J. Griffith, Paul F. Lambert, Richard Roden
Publikováno v:
Virology. 575
Human alphapapillomaviruses (αHPV) infect genital mucosa, and a high-risk subset is a necessary cause of cervical cancer. Licensed L1 virus-like particle (VLP) vaccines offer immunity against the nine most common αHPV associated with cervical cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c0b5428cbb3668bda86d9cbdf1cdea
https://pubmed.ncbi.nlm.nih.gov/36070626
https://pubmed.ncbi.nlm.nih.gov/36070626
Autor:
Pola Olczak, Ken Matsui, Margaret Wong, Jade Alvarez, Paul Lambert, Neil D. Christensen, Jiafen Hu, Bettina Huber, Reinhard Kirnbauer, Joshua W. Wang, Richard B. S. Roden
Publikováno v:
J Virol
The family of human papillomaviruses (HPV) includes over 400 genotypes. Genus α genotypes generally infect the anogenital mucosa, and a subset of these HPV are a necessary, but not sufficient, cause of cervical cancer. Of the 13 high-risk (HR) and 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9117743772370700091f106d97229fd1
https://europepmc.org/articles/PMC9278150/
https://europepmc.org/articles/PMC9278150/
Autor:
Brent V. Powell, Roosevelt Shaw, Alexis Barfield, Arnold L. Rheingold, Sujan Ghimire, Monet Stevenson, Douglas M. Ho, Saroj K. Pramanik, Jeanette A. Krause, Chao Chen, Tiara V. Hinton, Dipak Giri, Paul T. Wilder, Santosh K. Mandal, Angela Winstead, Pola Olczak, James M. Wachira, Samira Azemati, Tijesunimi Odebode, Hirendra N. Banerjee, Yongchao Zhang, Pumtiwitt C. McCarthy, James A. Golen, Peter Y. Zavalij, David J. Weber, Solomon Tadesse, Sabreea J. Parnell
Publikováno v:
Mol Cell Biochem
Cisplatin and other metal-based drugs often display side effects and tumor resistance after prolonged use. Because rhenium-based anticancer complexes are often less toxic, a novel series of organorhenium complexes were synthesized of the types: XRe(C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055444d774f2be768719004dd83f441c
https://doi.org/10.1007/s11010-017-3181-z
https://doi.org/10.1007/s11010-017-3181-z
Autor:
Ava Boston, Gabriel Thorne, Josiah Sampson, Santosh K. Mandal, Roosevelt Shaw, Brent V. Powell, Pola Olczak, Angela Winstead, Deidre Vaughan, Hirendra N. Banerjee, Vinod Manglik, Gloria Payne
Publikováno v:
Journal of cancer science & therapy
Purpose: Because of the scarcity of suitable brain cancer drugs, researchers are frantically trying to discover novel and highly potent drugs free of side effects and drug-resistance. Rhenium compounds are known to be nontoxic and exhibit no drug res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d08bd3c8512d6922fc801b42c797dc
https://doi.org/10.4172/1948-5956.1000512
https://doi.org/10.4172/1948-5956.1000512
Autor:
Jonathan M. White, Neil D. Christensen, Shizuko Sei, Brian P. Howard, Jiafen Hu, Michelle L. Kennedy, Christina Schellenbacher, Richard B.S. Roden, Joshua Weiyuan Wang, George W. Buchman, Robert H. Shoemaker, Reinhard Kirnbauer, Sarah A. Brendle, Pola Olczak, Ken Matsui, Huimin Tan, Karla K. Balogh, Elizabeth R. Glaze
Publikováno v:
Cancer Research. 79:LB-200
Background: The National Cancer Institute (NCI) PREVENT Cancer Program (PREVENT) is a peer-reviewed R&D pipeline with the core emphasis on preclinical development and clinical translation of novel cancer preventive interventions. One of the latest PR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db5baac85e7f26e08c35855602d95dc6
https://doi.org/10.1158/1538-7445.am2019-lb-200
https://doi.org/10.1158/1538-7445.am2019-lb-200
Autor:
Deidre Vaughan, Hirendra N. Banerjee, Fazlul H. Sarkar, Jewe Medley, Christopher Krauss, Carl Parson, Divine N. Kebulu, Michael K. Mbagu, Saroj K. Pramanik, Pola Olczak, Gwyn Hyman, Santosh K. Mandal
Publikováno v:
Cancer Research. 73:4485-4485
Cisplatin, carboplatin, oxaliplatin, and related metallodrugs are extensively being used in the treatment of a variety of cancers. Unfortunately these drugs are highly toxic and tumor becomes drug-resistance. These circumstances have led researchers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6691eb7581c47d1d323a87b47e7584b
https://doi.org/10.1158/1538-7445.am2013-4485
https://doi.org/10.1158/1538-7445.am2013-4485